Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 12:22PM ET
7.91
Dollar change
+0.07
Percentage change
0.83
%
Index- P/E- EPS (ttm)-42.58 Insider Own13.93% Shs Outstand2.69M Perf Week-1.06%
Market Cap21.29M Forward P/E- EPS next Y- Insider Trans-2.60% Shs Float2.32M Perf Month10.16%
Income-46.41M PEG- EPS next Q- Inst Own19.62% Short Float0.52% Perf Quarter2.79%
Sales0.00M P/S- EPS this Y- Inst Trans-6.34% Short Ratio0.40 Perf Half Y-11.66%
Book/sh4.17 P/B1.90 EPS next Y- ROA-63.23% Short Interest0.01M Perf Year-49.65%
Cash/sh20.84 P/C0.38 EPS next 5Y40.90% ROE-905.22% 52W Range5.10 - 19.57 Perf YTD13.07%
Dividend Est.- P/FCF- EPS past 5Y30.78% ROI-98.80% 52W High-59.56% Beta-1.85
Dividend TTM- Quick Ratio5.62 Sales past 5Y4.01% Gross Margin97.38% 52W Low55.20% ATR (14)0.33
Dividend Ex-Date- Current Ratio5.62 EPS Y/Y TTM24.36% Oper. Margin0.00% RSI (14)58.29 Volatility3.16% 4.03%
Employees34 Debt/Eq3.22 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price19.67
Option/ShortNo / Yes LT Debt/Eq3.19 EPS Q/Q-117.73% Payout- Rel Volume0.43 Prev Close7.85
Sales Surprise-100.00% EPS Surprise-14.43% Sales Q/Q-100.00% EarningsNov 13 BMO Avg Volume30.46K Price7.91
SMA203.35% SMA506.85% SMA200-17.78% Trades Volume6,315 Change0.83%
Date Action Analyst Rating Change Price Target Change
Mar-30-22Downgrade JP Morgan Neutral → Underweight
Aug-06-21Downgrade JP Morgan Overweight → Neutral
Sep-14-20Downgrade Jefferies Buy → Hold $10
Jul-23-20Initiated Northland Capital Outperform
Jun-01-20Resumed Oppenheimer Outperform $21
May-27-20Reiterated H.C. Wainwright Buy $14 → $17
Mar-09-20Upgrade BofA/Merrill Neutral → Buy
Dec-17-19Downgrade BofA/Merrill Buy → Neutral $9 → $6
Mar-14-19Initiated Jefferies Buy $15
Feb-26-24 08:00AM
Feb-06-24 08:00AM
Jan-19-24 04:01PM
Nov-13-23 08:00AM
Sep-20-23 04:01PM
08:00AM Loading…
Sep-05-23 08:00AM
Aug-15-23 10:20AM
Aug-04-23 08:11AM
08:00AM
Aug-02-23 04:01PM
08:00AM
Jul-19-23 04:01PM
Jun-23-23 04:01PM
Jun-02-23 08:00AM
May-11-23 12:20PM
08:07AM Loading…
May-09-23 08:07AM
08:00AM
Apr-28-23 08:00AM
Apr-14-23 12:49PM
Apr-13-23 11:22AM
11:10AM
Apr-12-23 08:00AM
Apr-05-23 05:50PM
Apr-04-23 01:32PM
01:16PM
Mar-30-23 05:50PM
Mar-29-23 08:00AM
Mar-28-23 11:04AM
Mar-27-23 08:00AM
Mar-24-23 09:55AM
11:09AM Loading…
Mar-23-23 11:09AM
Mar-22-23 09:30AM
07:37AM
Mar-20-23 12:04PM
09:30AM
Mar-17-23 02:54PM
Mar-09-23 09:30AM
Mar-08-23 04:01PM
09:55AM
Mar-06-23 12:33PM
Mar-03-23 03:02PM
08:00AM
Mar-02-23 09:30AM
Feb-22-23 05:50PM
Feb-14-23 05:45PM
Feb-08-23 05:45PM
Feb-01-23 04:25PM
Jan-19-23 09:30AM
Jan-17-23 10:00AM
Dec-30-22 12:02PM
02:59AM
Dec-29-22 09:55AM
Dec-28-22 11:13AM
09:44AM
06:48AM
Dec-27-22 04:01PM
Dec-20-22 10:03AM
09:06AM
Dec-07-22 09:55AM
Dec-06-22 01:22PM
Nov-28-22 04:02PM
04:01PM
Nov-10-22 06:26AM
Nov-08-22 08:00AM
Nov-01-22 07:30AM
Oct-20-22 07:30AM
Sep-06-22 08:00AM
Aug-19-22 04:01PM
Aug-18-22 04:01PM
Aug-11-22 09:41AM
08:15AM
07:00AM
Aug-09-22 09:35AM
Aug-08-22 09:00AM
Aug-04-22 04:01PM
Jul-22-22 04:01PM
Jul-11-22 08:00AM
Jul-06-22 12:00PM
Jun-17-22 04:01PM
Jun-02-22 08:00AM
May-26-22 11:03AM
May-23-22 06:29AM
12:01AM
May-16-22 08:15AM
07:00AM
May-12-22 07:15AM
May-11-22 08:15AM
May-10-22 09:55AM
May-09-22 08:00AM
May-03-22 08:00AM
May-02-22 01:10PM
May-01-22 09:00AM
Apr-27-22 03:03PM
Apr-04-22 04:01PM
Mar-29-22 08:15AM
07:00AM
Mar-23-22 08:00AM
Mar-14-22 03:11PM
Mar-08-22 08:00AM
Feb-18-22 04:00PM
KALA BIO, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Iwicki Mark TCHIEF EXECUTIVE OFFICERJan 04 '24Sale6.734,53930,547286,315Jan 05 04:04 PM
Brazzell Romulus KSEE REMARKSJan 04 '24Sale6.741,61710,89991,473Jan 05 04:05 PM
Kharabi DariusCHIEF BUSINESS OFFICERJan 04 '24Sale6.731,3859,32165,117Jan 05 04:06 PM
Reumuth MaryCHIEF FINANCIAL OFFICERJan 04 '24Sale6.741,2278,27066,136Jan 05 04:04 PM
Trachtenberg EricSEE REMARKSJan 04 '24Sale6.741,2278,27068,066Jan 05 04:07 PM